Effect of the Shingles Vaccine in Altering Clinical Shingles after Heart Transplantation
Herpes zoster, otherwise known as shingles, can be a devastating complication after heart transplantation due to persistent and severe herpetic neuralgia. Our heart transplant patients are recommended to have the shingles vaccine prior to heart transplantation, but this is not always achieved. We sought to assess whether the shingles vaccine did indeed prevent clinical shingles development after heart transplantation.
(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or... [Read More]
AbstractVaricella-zoster virus (VZV) is a pathogenic human herpesvirus that causes varicella (chickenpox) as a primary infection following which it becomes latent in ganglionic neurons. Following viral reactivation many years later VZV causes herpes zoster (shingles) as well as a variety of other neurological syndromes. The molecular mechanisms of the conversion of the virus from a lytic to a latent state in ganglia are not well understood. In order to gain insights into the neuron-virus interaction, we studied virus-induced apoptosis in cultures of both highly pure terminally differentiated human neurons and human fetal l...
Publication date: Available online 20 February 2020Source: IDCasesAuthor(s): Catherine Brahe, Rachel EllisAbstractLate diagnosis of HIV is associated with increased morbidity and mortality. Infected individuals need to be identified early and started on antiretroviral therapy to increase their survival and to limit transmission to the community. Historically speaking, late diagnosis has been a common occurrence in the United States, despite the majority of those patients having had a medical encounter in the year prior to their diagnosis. These visits represent missed opportunities for HIV testing and therefore delays in i...
Varicella zoster virus (VZV) is the causative agent of chickenpox (varicella) and shingles (herpes zoster). VZV and other members of the herpesvirus family are distinguished by their ability to establish a latent infection, with the potential to reactivate and spread virus to other susceptible individuals. This lifelong relationship continually subjects VZV to the host immune system and as such VZV has evolved a plethora of strategies to evade and manipulate the immune response. This review will focus on our current understanding of the innate anti-viral control mechanisms faced by VZV. We will also discuss the diverse arr...
Adults re-exposed to the herpes zoster virus found to be around 30% less likely to develop shingles Related items fromOnMedica GPs are dealing with growing flu rates Experts predict 'invigorated' winter flu Illness poorly managed in those with learning disability Flu activity appears to be nearing its peak Doctors can help overcome ‘vaccine hesitancy’
These reports provide an evaluation of the shingles vaccination programme in England from 2018 to 2019.
Herpes zoster infection occurs in 1 of 3 people in their lifetime. The virus can be painful and place a large physical and financial burden on those affected. Once the virus activates, it can lead to a painful, blistery rash. The pain can last for months to years. More than 10% of patients who develop shingles will experience a complication, including blindness, neuropathic pain, and cerebrovascular events. Clinicians must be astute in recognizing the symptoms to treat quickly. Effective treatment for herpes zoster is prevention.
The Advisory Committee on Immunization Practices (ACIP) recommends that adults aged ≥19 years receive various vaccines to prevent serious health conditions, including hepatitis B, herpes zoster/shingles, human papilloma virus (HPV), and pneumonia. Recent vaccine approvals by the US Food and Drug Administration (FDA) have led to updates in the ACIP adult immunization schedule. Thi s article provides a relevant clinical literature review for nurse practitioners on the newly approved vaccines for hepatitis B and herpes zoster and updated ACIP recommendations.
This NIHR Signal says that the risk of shingles is about 10% per year in adults after autologous stem cell transplant. The evidence summary indicates that two doses of deactivated herpes zoster vaccine could be a safe and effective way to reduce that risk by about two thirds.This effect is similar to another, heat-treated, non-live vaccine. Either vaccine could reduce the pain and need for medical treatment associated with shingles, and long-lasting complications such as post-herpetic neuralgia. It's not yet known if people need to continue taking acyclovir as well.